These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6107677)

  • 1. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity.
    Stunkard AJ; Craighead LW; O'Brien R
    Lancet; 1980 Nov; 2(8203):1045-7. PubMed ID: 6107677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavior therapy and pharmacotherapy for obesity.
    Craighead LW; Stunkard AJ; O'Brien RM
    Arch Gen Psychiatry; 1981 Jul; 38(7):763-8. PubMed ID: 7247639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Couples training, pharmacotherapy, and behavior therapy in the treatment of obesity.
    Brownell KD; Stunkard AJ
    Arch Gen Psychiatry; 1981 Nov; 38(11):1224-9. PubMed ID: 7305602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of fenfluramine in treatment of obesity.
    Douglas JG; Gough J; Preston PG; Frazer I; Haslett C; Chalmers SR; Munro JF
    Lancet; 1983 Feb; 1(8321):384-6. PubMed ID: 6130379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.
    Durnin JV; Womersley J
    Br J Pharmacol; 1973 Sep; 49(1):115-20. PubMed ID: 4595485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management strategies for weight control. Eating, exercise and behaviour.
    Caterson ID
    Drugs; 1990; 39 Suppl 3():20-32. PubMed ID: 2197073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of compulsive eating disorders in an autistic girl by combining behavior therapy and pharmacotherapy. Case report].
    Hackler J
    Z Kinder Jugendpsychiatr; 1986; 14(3):220-7. PubMed ID: 3765895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.
    Weintraub M; Sundaresan PR; Madan M; Schuster B; Balder A; Lasagna L; Cox C
    Clin Pharmacol Ther; 1992 May; 51(5):586-94. PubMed ID: 1587072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions.
    Avenell A; Brown TJ; McGee MA; Campbell MK; Grant AM; Broom J; Jung RT; Smith WC
    J Hum Nutr Diet; 2004 Aug; 17(4):293-316. PubMed ID: 15250841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fenfluramine on weight loss during restricted dietary regimes.
    Wales JK
    Int J Obes; 1980; 4(2):127-32. PubMed ID: 7399803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulatory effects of fenfluramine in obese hypertensive patients.
    Mroczek WJ; Lee WR; Finnerty FA
    Curr Ther Res Clin Exp; 1974 Nov; 16(11):1197-202. PubMed ID: 4214654
    [No Abstract]   [Full Text] [Related]  

  • 16. Fenfluramine in corticosteroid-induced obesity.
    Cameron DC; Kennedy WP; Samuel PD; Crompton GK
    Curr Med Res Opin; 1972; 1(3):153-8. PubMed ID: 4589709
    [No Abstract]   [Full Text] [Related]  

  • 17. Body weight evolution during dexfenfluramine treatment after initial weight control.
    Finer N
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S25-9. PubMed ID: 1338319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind clinical trial of fenfluramine.
    Lele RD; Joshi VR; Nathwani AN
    Br J Clin Pract; 1972 Feb; 26(2):79-82. PubMed ID: 4552745
    [No Abstract]   [Full Text] [Related]  

  • 19. Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
    Rickels K; Hesbacher P; Fisher E; Perloff MM; Rosenfeld H
    Psychol Med; 1976 Nov; 6(4):623-30. PubMed ID: 794895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
    Pfohl M; Luft D; Blomberg I; Schmülling RM
    Int J Obes Relat Metab Disord; 1994 Jun; 18(6):391-5. PubMed ID: 8081430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.